drugset / Trial / NCT02431481

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481

Phase 1 Completed 38 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the PK and safety profile of LEE011 following a single oral dose in adult subjects with various degrees of renal impairment compared to a matched group of healthy subjects with normal renal function.

Timeline

Start
2015-10-23
Primary completion
2017-09-14
Completion
2018-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule 400 mg Oral